A Novel Therapeutic

We’re creating the first potential treatment for Demodex blepharitis

What is TP-03?

TP-03 is a topical ophthalmic formulation of lotilaner that, if approved, may offer treatment for millions of patients with Demodex blepharitis.¹

Up to 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.^1-3

TP-03 may change that.

Designed to resolve the signs of Demodex blepharitis by targeting and eradicating the root cause of the disease–Demodex mite infestation²
Paralyzes and eradicates Demodex mites by selectively inhibiting parasite-specific GABA-Cl channels²
Evaluated in 2 pivotal trials collectively involving 833 patients, both of which successfully met all primary and secondary end points; TP-03 had no serious treatment-related adverse events and was generally safe and well tolerated¹
TP-03 may potentially become the first FDA-approved therapy and definitive standard of care to treat millions of patients with Demodex blepharitis, if approved¹

The active ingredient in TP-03 is lotilaner, a well-characterized antiparasitic agent that targets parasite-specific GABA-CI channels.¹

Learn More About Demodex Blepharitis

Saturn-1 Phase 2b/3 Pivotal Trial

Presented by Elizabeth Yeu, MD, at ASCRS 2021 Annual Meeting.

References

1. Tarsus announces positive topline data from Saturn-2 Phase 3, the second pivotal trial of TP-03 for the treatment of Demodex blepharitis, and expects to file a new drug application this year. News release. Tarsus Pharmaceuticals, Inc; May 2, 2022. 2. Tarsus Pharmaceuticals, Inc. announces positive results of Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis. Tarsus Pharmaceuticals, Inc. Press release. July 21, 2021. 3. Sadri E, Yeu L, Trattler W, Holdbrook M, Baba S. The prevalence of collarettes and Demodex blepharitis in ophthalmology and optometry practices. Presented at: ASCRS 2021. July 24, 2021; Las Vegas, NV. 4. Wilson FA, Stimpson JP, Wang Y. Inconsistencies exist in national estimates of eye care services utilization in the United States. J Ophthalmol. Published online August 9, 2015. doi:10.1155/2015/435606

Contact Tarsus

Please reach out to us using the form below.

"*" indicates required fields